COMPANY
Switch Therapeutics
NIH awards 1
- NIH award 1R44AG102082-01 FY2026: $1,609,473 awarded for that fiscal year; activity R44 (SBIR); PI BLANCHETTE, CRAIG; recipient as written: SWITCH THERAPEUTICS INC., SOUTH SAN FRANCISCO, CA. Liver-Sparing APOE Inhibi source ↗
Funding and NIH signals
- NIH award NIH awarded $1.61M (SBIR Phase II 1R44AG102082-01, new, notice Sep 17, 2026). NIH RePORTER 1R44AG102082-01 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R44AG102082-01
Organization: SWITCH THERAPEUTICS INC.; City/State: SOUTH SAN FRANCISCO, CA; Project number: 1R44AG102082-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1609473; Administering IC: National Institute on Aging; Project title: Liver-Sparing APOE Inhibitor for the Treatment of Alzheimer's Disease in APOE4 Homozygotes; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R44AG102082-01